NasdaqGM:OCSPharmaceuticals
Oculis Holding (OCS) Is Down 60.1% After OCS-01 Trial Failure And Pipeline Pivot – Has The Bull Case Changed?
Oculis Holding AG recently reported that its Phase 3 DIAMOND-1 and DIAMOND-2 trials of OCS-01 eye drops in diabetic macular edema failed to meet primary and key secondary visual acuity endpoints, leading the company to halt plans for an FDA filing in this indication.
While vision-related endpoints fell short, the trials showed persistent reductions in retinal thickness and prompted Oculis to reallocate its strong US$278 million cash position toward advancing privosegtor in optic neuropathies...